Deciphera Pharmaceuticals Inc.'s ripretinib met and potentially exceeded expectations in the placebo-controlled Phase III INVICTUS clinical trial testing the KIT and PDGFRa kinase switch control inhibitor in fourth-line treatment of gastrointestinal stromal tumors (GIST), justifying the filing of a new drug application (NDA) with the US Food and Drug Administration in the first quarter of 2020.
The company reported median progression-free survival (mPFS) in INVICTUS – the trial's primary endpoint – of 6.3 months (27.6 weeks)...